中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity

文献类型：期刊论文

作者Long, Yiru2,3; Sun, Jianhua2,3; Song, Tian-Zhang3,4; Liu, Tingting2; Tang, Feng2,3; Zhang, Xinxin2,3; Ding, Longfei5,6; Miao, Yunqiu2,3; Zhu, Weiliang2,3; Pan, Xiaoyan3,7
刊名CELL DISCOVERY
出版日期2022-02-01
卷号8期号:1页码:16
DOI10.1038/s41421-021-00370-2
通讯作者Qin, Qiuping(qpqin@cdser.simm.ac.cn) ; Gan, Yong(ygan@simm.ac.cn) ; Ren, Jin(jren@cdser.simm.ac.cn) ; Huang, Wei(huangwei@simm.ac.cn) ; Zheng, Yong-Tang(zhengyt@mail.kiz.ac.cn) ; Jin, Guangyi(gyjin@szu.edu.cn) ; Gong, Likun(lkgong@simm.ac.cn)
英文摘要Safe, effective, and economical vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and end the pandemic. We constructed a novel SARS-CoV-2 vaccine, CoVac501, which is a self-adjuvanting peptide vaccine conjugated with Toll-like receptor 7 (TLR7) agonists. The vaccine contains immunodominant peptides screened from the receptor-binding domain (RBD) and is fully chemically synthesized. It has been formulated in an optimized nanoemulsion formulation and is stable at 40 degrees C for 1 month. In non-human primates (NHPs), CoVac501 elicited high and persistent titers of protective neutralizing antibodies against multiple RBD mutations, SARS-CoV-2 original strain, and variants (B.1.1.7 and B.1.617.2). Specific peptides booster immunization against the B.1.351 variant has also been shown to be effective in improving protection against B.1.351. Meanwhile, CoVac501 elicited the increase of memory T cells, antigen-specific CD8(+) T-cell responses, and Th1-biased CD4(+) T-cell immune responses in NHPs. Notably, at an extremely high SARS-CoV-2 challenge dose of 1 x 10(7) TCID50, CoVac501 provided near-complete protection for the upper and lower respiratory tracts of cynomolgus macaques.
WOS关键词RESPONSES ; PROGRESS ; DOMAIN
资助项目National New Drug Creation Program of China[2019ZX09732002-013] ; National New Drug Creation Program of China[2018ZX09201017-004] ; Strategic Priority Research Program of the Chinese Academy of Sciences[XDA 12050305] ; Fundamental Research Funds for the State Key Laboratory of Drug Research[SIMM2103ZZ-01] ; National Key R&D Program of China[2020YFC0842000] ; Institutes for Drug Discovery and Development, Chinese Academy of Sciences[CASIMM0120202002]
WOS研究方向Cell Biology
语种英语
WOS记录号WOS:000750517700003
出版者SPRINGERNATURE
源URL[http://119.78.100.183/handle/2S10ELR8/300170]  
专题新药研究国家重点实验室
通讯作者Qin, Qiuping; Gan, Yong; Ren, Jin; Huang, Wei; Zheng, Yong-Tang; Jin, Guangyi; Gong, Likun
作者单位1.Mabwell Shanghai Biosci Co Ltd, Shanghai, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China
3.Univ Chinese Acad Sci, Beijing, Peoples R China
4.Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Kunming, Yunnan, Peoples R China
5.Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China
6.Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China
7.Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Hubei, Peoples R China
8.Shanghai King Cell Biotechnol Co Ltd, Shanghai, Peoples R China
9.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Inst Drug Discovery & Dev, Zhongshan, Guangdong, Peoples R China
10.Shenzhen Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Shenzhen, Guangdong, Peoples R China
推荐引用方式
GB/T 7714		 Long, Yiru,Sun, Jianhua,Song, Tian-Zhang,et al. CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity[J]. CELL DISCOVERY,2022,8(1):16.
APA Long, Yiru.,Sun, Jianhua.,Song, Tian-Zhang.,Liu, Tingting.,Tang, Feng.,...&Gong, Likun.(2022).CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity.CELL DISCOVERY,8(1),16.
MLA Long, Yiru,et al."CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity".CELL DISCOVERY 8.1(2022):16.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。